Conferences - Results from #7960

ASCO 2018: A Pilot Randomized Study Evaluating Nivolumab or Nivo + Bevacizumab or Nivo + Ipilimumab in Patients with Metastatic Renal Cell Carcinoma Eligible for Cytoreductive Nephrectomy, Metastasectomy or Post-treatment Biopsy June 3, 2018

ASCO 2018: CARMENA: Cytoreductive Nephrectomy Followed by Sunitinib vs. Sunitinib Alone in Metastatic Renal Cell Carcinoma - Results of a Phase III Noninferiority Trial June 3, 2018

ASCO 2018: Gut Microbiome Composition to Predict Resistance in Renal Cell Carcinoma Patients on Nivolumab June 3, 2018

ASCO 2018: Correlation of Degree of Tumor Immune Infiltration and Insertion-and-Deletion Burden with Outcome on Programmed Death 1 Therapy in Advanced Renal Cell Cancer June 3, 2018

ASCO 2018: Relationship of Time to Metastasis and Site of Metastases in Patients with Nonmetastatic CRPC: Results from the Phase 3 SPARTAN Trial June 3, 2018

ASCO 2018: Prostate Radiotherapy in Newly-Diagnosed Metastatic Hormone-Sensitive Prostate Cancer June 3, 2018

ASCO 2018: Prospective Phase II Multi-Center Study of Individualized Axitinib Titration for Metastatic Renal Cell Carcinoma After Treatment with PD-1 / PD-L1 Inhibitors June 3, 2018

ASCO 2018: Cctg BL12: Randomized Phase II Trial Comparing Nab-Paclitaxel to Paclitaxel in Patients with Advanced Urothelial Cancer Progressing On or After a Platinum Containing Regimen June 3, 2018

ASCO 2018: Phase II Safety and Tolerability Study of Radium-223 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: CTRIAL-IE (ICORG) 13-21 June 3, 2018

ASCO 2018: Pembrolizumab Plus Enzalutamide in Metastatic Castration Resistant Prostate Cancer: Extended Follow Up June 3, 2018

ASCO 2018: A Phase 3, Randomized, Open-label Study of Nivolumab Combined with Cabozantinib vs Sunitinib in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma June 3, 2018

ASCO 2018: PROSPER: A Phase III Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy June 3, 2018

ASCO 2018: PECULIAR: An Open Label, Multicenter, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab and Epacadostat, Preceding Radical Cystectomy, for Patients with Muscle-invasive Urothelial Bladder Cancer June 3, 2018

ASCO 2018: Updated Results from the Enfortumab Vedotin Phase 1 (EV-101) Study in Patients with Metastatic Urothelial Cancer June 3, 2018

ASCO 2018: First Results from the Primary Analysis Population of the Phase 2 Study of Erdafitinib in Patients with Metastatic or Unresectable Urothelial Carcinoma and FGFR Alterations June 3, 2018

ASCO 2018: Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade June 3, 2018

ASCO 2018: Lutetium-177 PSMA617 Theranostics In Metastatic Castrate-Resistant Prostate Cancer: Interim Results of a Phase II Trial June 3, 2018

ASCO 2018: A Randomized Phase 2 Trial of Pazopanib vs. Temsirolimus in Patients with Advanced Clear-Cell Renal Cell Carcinoma with Intermediate or Poor-risk Disease (The TemPa Trial) June 3, 2018

ASCO 2018: SPIRE: A Phase 1b/Randomized 2a Open Label Clinical Trial Combining Guadecitabine (SGI-110) with Cisplatin and Gemcitabine Chemotherapy for Solid Malignancies Including Bladder Cancer June 3, 2018

ASCO 2018: Lenvatinib + Pembrolizumab in Patients with Renal Cell Carcinoma: Updated Results June 3, 2018

Page 399 of 616